Viridian Therapeutics, Inc. (VRDN) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $16.08 (-1.13%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 8, 2026 | Laura Chico | Wedbush | $31.00 | +92.8% |
| Feb 26, 2026 | Kelly Shi | Jefferies | $45.00 | +179.9% |
| Jan 28, 2026 | Gavin Clark-Gartner | Evercore ISI | $45.00 | +179.9% |
| Jan 20, 2026 | Gavin Clark-Gartner | Evercore ISI | $44.00 | +173.6% |
| Nov 5, 2025 | Alex Thompson | Stifel Nicolaus | $48.00 | +198.5% |
| Oct 21, 2025 | Douglas Tsao | H.C. Wainwright | $34.00 | +111.4% |
| Nov 12, 2024 | Alex Thompson | Stifel Nicolaus | $20.50 | +27.5% |
| Sep 13, 2024 | Gregory Renza | RBC Capital | $22.00 | +36.8% |
| Sep 11, 2024 | Serge Belanger | Needham | $19.00 | +18.2% |
| Sep 11, 2024 | Kalpit Patel | B.Riley Financial | $22.00 | +36.8% |
| Sep 10, 2024 | Alex Thompson | Stifel Nicolaus | $20.00 | +24.4% |
| Sep 10, 2024 | Julian Harrison | BTIG | $28.00 | +74.1% |
| Aug 14, 2024 | Richard Law | Goldman Sachs | $25.00 | +55.5% |
| Jun 11, 2024 | Gregory Renza | RBC Capital | $17.50 | +8.8% |
| Jun 11, 2024 | Julian Harrison | BTIG | $23.00 | +43.0% |
| Jun 10, 2024 | Andy Chen | Wolfe Research | $14.50 | -9.8% |
| Jun 6, 2024 | Richard Law | Goldman Sachs | $11.50 | -28.5% |
| May 9, 2024 | Leland Gershell | Oppenheimer | $15.50 | -3.6% |
| May 9, 2024 | Douglas Tsao | H.C. Wainwright | $13.50 | -16.0% |
| May 9, 2024 | Kalpit Patel | B.Riley Financial | $20.00 | +24.4% |
Top Analysts Covering VRDN
VRDN vs Sector & Market
| Metric | VRDN | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.11 | 2.24 | 2.40 |
| Analyst Count | 19 | 8 | 19 |
| Target Upside | +124.9% | +11474.9% | +17.1% |
| P/E Ratio | -3.37 | 3.91 | 31.64 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $4M | $10M | $15M | 7 |
| 2026-09-30 | $7M | $17M | $28M | 4 |
| 2026-12-31 | $13M | $32M | $51M | 4 |
| 2027-03-31 | $19M | $48M | $77M | 4 |
| 2027-06-30 | $26M | $64M | $102M | 3 |
| 2027-09-30 | $31M | $78M | $125M | 3 |
| 2027-12-31 | $51M | $127M | $203M | 3 |
| 2028-12-31 | $594M | $598M | $602M | 11 |
| 2029-12-31 | $417M | $860M | $1.78B | 5 |
| 2030-12-31 | $538M | $1.11B | $2.30B | 5 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-30 | $-1.40 | $-1.03 | $-0.23 | 8 |
| 2026-09-30 | $-1.76 | $-0.99 | $-0.22 | 3 |
| 2026-12-31 | $-1.58 | $-0.89 | $-0.19 | 6 |
| 2027-03-31 | $-1.32 | $-0.74 | $-0.16 | 3 |
| 2027-06-30 | $-1.20 | $-0.68 | $-0.15 | 5 |
| 2027-09-30 | $-1.09 | $-0.61 | $-0.14 | 3 |
| 2027-12-31 | $-0.58 | $-0.33 | $-0.07 | 6 |
| 2028-12-31 | $-10.97 | $-0.12 | $9.27 | 10 |
| 2029-12-31 | $0.59 | $1.80 | $4.30 | 4 |
| 2030-12-31 | $1.05 | $3.17 | $7.57 | 4 |
Frequently Asked Questions
What is the analyst consensus for VRDN?
The consensus among 19 analysts covering Viridian Therapeutics, Inc. (VRDN) is Buy with an average price target of $42.67.
What is the highest price target for VRDN?
The highest price target for VRDN is $48.00, set by Alex Thompson at Stifel Nicolaus on 2025-11-05.
What is the lowest price target for VRDN?
The lowest price target for VRDN is $11.50, set by Richard Law at Goldman Sachs on 2024-06-06.
How many analysts cover VRDN?
19 analysts have issued ratings for Viridian Therapeutics, Inc. in the past 12 months.
Is VRDN a buy or sell right now?
Based on 19 analyst ratings, VRDN has a consensus rating of Buy (2.11/5) with a +124.9% upside to the consensus target of $42.67.
What are the earnings estimates for VRDN?
Analysts estimate VRDN will report EPS of $-1.03 for the period ending 2026-06-30, with revenue estimated at $10M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.